Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Change in Receivables (2021 - 2025)

Oncology Institute (TOI) has disclosed Change in Receivables for 5 consecutive years, with $12.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Receivables rose 2522.89% year-over-year to $12.7 million, compared with a TTM value of $602000.0 through Sep 2025, down 96.43%, and an annual FY2024 reading of -$205000.0, down 104.49% over the prior year.
  • Change in Receivables was $12.7 million for Q3 2025 at Oncology Institute, up from $228000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $16.4 million in Q1 2024 and bottomed at -$12.3 million in Q4 2024.
  • Average Change in Receivables over 5 years is $971111.1, with a median of $331500.0 recorded in 2023.
  • The sharpest move saw Change in Receivables plummeted 13812.68% in 2022, then surged 14521.43% in 2023.
  • Year by year, Change in Receivables stood at $473000.0 in 2021, then tumbled by 87.74% to $58000.0 in 2022, then skyrocketed by 8032.76% to $4.7 million in 2023, then tumbled by 361.76% to -$12.3 million in 2024, then soared by 203.03% to $12.7 million in 2025.
  • Business Quant data shows Change in Receivables for TOI at $12.7 million in Q3 2025, $228000.0 in Q2 2025, and -$12.3 million in Q4 2024.